- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04819269
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
February 16, 2024 updated by: Sylentis, S.A.
This study will examine the efficacy and safety of tivanisiran sodium eye drops versus vehicle after a 2-week run-in phase when dosed once daily for 3 months in subjects with signs and symptoms of dry eye disease (DED) due to Sjögren's Syndrome.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
203
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Barcelona, Spain, 08022
- Sylentis Investigative Site
-
Madrid, Spain, 28034
- Sylentis Investigative Site
-
Madrid, Spain, 28040
- Sylentis Investigative Site
-
Sevilla, Spain, 41009
- Sylentis Investigative Site
-
Valladolid, Spain, 47003
- Sylentis Investigative Sites
-
Zaragoza, Spain, 50004
- Sylentis Investigative Site
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Sylentis Investigative Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Sylentis Investigative Site
-
Dothan, Alabama, United States, 36301
- Sylentis Investigative Site
-
-
Arizona
-
Scottsdale, Arizona, United States, 85254
- Sylentis Investigative Site
-
-
California
-
Garden Grove, California, United States, 92843
- Sylentis Investigative Site
-
Glendale, California, United States, 91204
- Sylentis Investigative Site
-
Los Angeles, California, United States, 90013
- Sylentis Investigative Site
-
Newport Beach, California, United States, 92663
- Sylentis Investigative Site
-
Rancho Cordova, California, United States, 95670
- Sylentis Investigative Site
-
San Diego, California, United States, 92122
- Sylentis Investigative Site
-
Torrance, California, United States, 90505
- Sylentis Investigative Site
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Sylentis Investigative Site
-
Colorado Springs, Colorado, United States, 80907
- Sylentis Investigative Site
-
Littleton, Colorado, United States, 80120
- Sylentis Investigative Site
-
-
Florida
-
Jacksonville, Florida, United States, 32256
- Sylentis Investigative Site
-
Largo, Florida, United States, 33773
- Sylentis Investigative Site
-
Miami, Florida, United States, 33136
- Sylentis Investigative Site
-
Ormond Beach, Florida, United States, 32174
- Sylentis Investigative Site
-
Tampa, Florida, United States, 33603
- Sylentis Investigative Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30339
- Sylentis Investigative Site
-
Morrow, Georgia, United States, 30260
- Sylentis Investigative Site
-
-
Indiana
-
Carmel, Indiana, United States, 46290
- Sylentis Investigative Site
-
-
Massachusetts
-
Waltham, Massachusetts, United States, 02451
- Sylentis Investigative Site
-
-
Michigan
-
Ypsilanti, Michigan, United States, 48197
- Sylentis Investigative Site
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Sylentis Investigative Site
-
Saint Louis, Missouri, United States, 63131
- Sylentis Investigative Site
-
Washington, Missouri, United States, 63090
- Sylentis Investigative Site
-
-
North Carolina
-
Asheville, North Carolina, United States, 28803
- Sylentis Investigative Site
-
High Point, North Carolina, United States, 27262
- Sylentis Investigative Site
-
-
North Dakota
-
Fargo, North Dakota, United States, 58103
- Sylentis Investigative Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44115
- Sylentis Investigative Site
-
Columbus, Ohio, United States, 43215
- Sylentis Investigative Site
-
-
Pennsylvania
-
Cranberry Township, Pennsylvania, United States, 16066
- Sylentis Investigative Site
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57701
- Sylentis Investigative Site
-
-
Tennessee
-
Memphis, Tennessee, United States, 38103
- Sylentis Investigative Site
-
Nashville, Tennessee, United States, 37215
- Sylentis Investigative Site
-
-
Texas
-
El Paso, Texas, United States, 79902
- Sylentis Investigative Site
-
Houston, Texas, United States, 77030
- Sylentis Investigative Site
-
Houston, Texas, United States, 77034
- Sylentis Investigative Site
-
-
Virginia
-
Falls Church, Virginia, United States, 22042
- Sylentis Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subject is a male or a female aged ≥ 18 years
- Have given their written consent to participate in the study
- Use of artificial tears (AT), autologous serum or specific dry eye medications during the last 6 months prior to the selection
- Willing to not use AT or autologous serum for the study duration
- VAS scale for Dry Eye Symptom Score ≥ 40
- Total CFS ≥ 5
- Schirmer's test with anesthesia < 10 mm/5min
- Patients with Sjögren Syndrome
Exclusion Criteria:
- Any concomitant treatment or prior ocular procedure or surgery, or alteration of the dose of systemic medications at the time of entry into the study
- Use of contact lenses during the study
- Significant Eye diseases according to investigator's opinion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Vehicle ophthalmic solution
|
1 drop in the affected eye(s) once daily
|
Active Comparator: Tivanisiran sodium ophthalmic solution
|
1 drop in the affected eye(s) once daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in Corneal Fluorescein Staining (CFS) scale [0-3]. Higher scores mean disease worsening.
Time Frame: 85 days
|
85 days
|
Change from baseline in Dry Eye Symptom scale [0-100]. Higher scores mean disease worsening.
Time Frame: 85 days
|
85 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 25, 2021
Primary Completion (Actual)
December 11, 2023
Study Completion (Actual)
December 11, 2023
Study Registration Dates
First Submitted
March 24, 2021
First Submitted That Met QC Criteria
March 24, 2021
First Posted (Actual)
March 26, 2021
Study Record Updates
Last Update Posted (Actual)
February 20, 2024
Last Update Submitted That Met QC Criteria
February 16, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Disease
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Stomatognathic Diseases
- Mouth Diseases
- Lacrimal Apparatus Diseases
- Keratoconjunctivitis
- Conjunctivitis
- Conjunctival Diseases
- Keratitis
- Corneal Diseases
- Arthritis, Rheumatoid
- Xerostomia
- Salivary Gland Diseases
- Syndrome
- Eye Diseases
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- Sjogren's Syndrome
- Ophthalmic Solutions
- Pharmaceutical Solutions
Other Study ID Numbers
- SYL1001_V
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye Disease
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
Gordon Schanzlin New VisionCompletedDry Eye | Dry Eye Disease | Evaporative Dry Eye | Kerato Conjunctivitis Sicca | Evaporative Dry Eye Disease | Dry Eye, EvaporativeUnited States
-
Laboratorios Sophia S.A de C.V.Not yet recruitingOcular Surface Disease | Dry Eye Disease | Dry Eye Sensation
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
LantibioRiver Plate Biotechnology, Inc.; Rx Development Resources, LLCCompletedSafety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye SyndromeDry Eye DiseaseUnited States
-
Fundación Oftalmológica Los AndesAlcon ResearchNot yet recruitingCataract | Dry Eye Syndrome | Dry Eye Disease | Phacoemulsification | Evaporative Dry Eye
-
Vienna Institute for Research in Ocular SurgeryTerminated
-
Novaliq GmbHCompletedDry Eye Disease (DED)United States
-
Novaliq GmbHCompletedDry Eye Disease (DED)United States
Clinical Trials on Tivanisiran sodium ophthalmic solution
-
Sylentis, S.A.Completed
-
Peking University Third HospitalRecruitingDry Eye Syndromes | Computer Vision Syndrome | AsthenopiaChina
-
Laboratorios Sophia S.A de C.V.WithdrawnConjunctivitis, Allergic | Seasonal Allergic Conjunctivitis | Ocular Itching | Ocular Allergy | Perennial Allergic ConjunctivitisMexico
-
Alcon ResearchCompletedOcular Hypertension | Open-angle Glaucoma
-
Santen Pharmaceutical Co., Ltd.CompletedPrimary Open Angle Glaucoma | Ocular HypertensionJapan
-
Aldeyra Therapeutics, Inc.Completed
-
Mimetogen Pharmaceuticals USA, Inc.CompletedDry Eye SyndromesUnited States
-
Aldeyra Therapeutics, Inc.CompletedAllergic ConjunctivitisUnited States
-
Aldeyra Therapeutics, Inc.Completed